Holen Sie sich die Stockscreener-App
38.76
3.78%
1.41
Vorhandelsmarkt:
39.93
1.17
+3.02%
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Brokers Offer Predictions for CRNX FY2025 Earnings - MarketBeat
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Increase in Short Interest - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Up 3.12%: This Is What Analysts Are Now Forecasting - Stocks Register
Crinetics falls after mid-stage trial data adrenal disorder therapy - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Receives “Buy” Rating from HC Wainwright - Defense World
Crinetics Pharmaceuticals' (CRNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by JPMorgan Chase & Co. - Defense World
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Grants Stock Options to 17 New Employees in Key Expansion Move - StockTitan
Crinetics reports positive results in CAH treatment study By Investing.com - Investing.com Australia
Crinetics stock falls after CAH therapy data (CRNX:NASDAQ) - Seeking Alpha
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2 - TipRanks
Crinetics reports positive results in CAH treatment study - Investing.com India
Crinetics Announces Positive Topline Results From Phase 2 - GlobeNewswire
Crinetics' CAH Drug Atumelnant Shows Remarkable 80% Biomarker Reduction in Phase 2 Trial Success - StockTitan
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth as pipeline advances - Investing.com Nigeria
Crinetics Pharmaceuticals' SWOT analysis: stock poised for growth as pipeline advances - Investing.com India
Crinetics stock maintains rating at Overweight on recent approval By Investing.com - Investing.com Canada
Trading (CRNX) With Integrated Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals chief sells shares worth $781,350 - Investing.com
Crinetics Pharmaceuticals chief sells shares worth $781,350 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.5%What's Next? - MarketBeat
Crinetics Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Raises Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness (NASDAQ:CRNX) - Seeking Alpha
Berkshire Hathaway Cl A (BRK-A-N) QuotePress Release - The Globe and Mail
Stifel Financial Corp Sells 520 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - News & Insights
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):